Professor and Chair, Department of Urology, University of California, Davis.
Urology
Dr. Christopher P. Evans, MD
|
|
Give Review
Dr. Christopher P. Evans is an expert in the field of Urology. He went to medical school at Geisel School of Medicine at Dartmouth. Geisel School of Medicine at Dartmouth is ranked 37 in research and 29 in primary care medicine He received awards:"CMS Meaningful Use Stage 1 Certification", "Fellow (FACS)" and "Super Doctor". Christopher P. Evans, MD is a published doctor and has 94 publications published. The lastest was: 'miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2 and Src.' Christopher Evans accepts all Medicare patients.
Publications
- miR-124 and androgen receptor signaling inhibitors repress prostate Cancer growth by downregulating androgen receptor splice variants, EZH2 and Src.
- Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
- Impact of synchronous metastasis distribution on Cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy.
- Ultrasensitive Prostate-Specific Antigen and its Role after Radical Prostatectomy: a Systematic Review.
- Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level.
- Molecular pathways and targets in prostate Cancer.
- Autophagy as a modulator and target in prostate Cancer.
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy.
- miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.
- Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).
- The changing landscape of advanced and castration resistant prostate Cancer: latest science and revised definitions.
- Niclosamide inhibits androgen receptor variants expression and overcomes Enzalutamide resistance in castration resistant prostate Cancer.
- Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate Cancer cells and improves therapeutic response in a xenograft model.
- Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate Cancer cells.
- Dasatinib and docetaxel in advanced prostate Cancer.
- No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate Cancer over a 20-year period.
- lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs.
- Lin28 promotes growth of prostate Cancer cells and activates the androgen receptor.
- Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate Cancer.
- Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus.
- NF-kappaB2/p52 induces resistance to Enzalutamide in Prostate Cancer: Role of androgen receptor and its variants.
- Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy.
- Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis.
- Economic analysis of active surveillance for localized prostate Cancer.
- Defining an individualized treatment strategy for metastatic renal Cancer.
- Evidence that behavioral phenotypes of morphine in β-arr2-/- mice are due to the unmasking of JNK signaling.
- MicroRNA let-7c Is Downregulated in Prostate Cancer and Suppresses Prostate Cancer Growth.
- Active surveillance for prostate Cancer compared with immediate treatment: An economic analysis.
- MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate Cancer cells.
- Traditional approaches to androgen deprivation therapy.
- Pretreatment Imaging Can Be Used to Select Imaging Guidance, Ultrasound Alone Versus CT Plus Ultrasound, for Percutaneous Renal Radiofrequency Ablation.
- Simultaneous targeting of src kinase and receptor tyrosine kinase results in synergistic inhibition of Renal cell carcinoma proliferation and migration.
- RhoGDI? suppresses growth and survival of prostate Cancer cells.
- Effect of Age on Transitional Cell Carcinoma of the Upper Urinary Tract: Presentation, Treatment, and Outcomes.
- Inhibition of Stat3 activation by sanguinarine suppresses prostate Cancer cell growth and invasion.
- Palliative care in urology.
- Secondary malignancies among nonseminomatous germ cell tumor Cancer survivors.
- Andrographolide targets androgen receptor pathway in castration-resistant prostate Cancer.
- What is the optimal management of high risk, clinically localized prostate Cancer?
- Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate Cancer cell growth.
- Effect of the Specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
- Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate Cancer cells.
- Sanguinarine Suppresses Prostate Tumor Growth and Inhibits Survivin Expression.
- Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors.
- Adjuvant chemotherapy for high risk upper Tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration.
- Interleukin-6 regulates androgen synthesis in prostate Cancer cells.
- Trends in Pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004.
- The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung Cancer cells.
- Interleukin-6 increases prostate Cancer cells resistance to bicalutamide via TIF2.
- SUO/SBUR 2007 annual meeting proceedings: overview.
- Oncogenic activation of androgen receptor.
- Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate Cancer.
- Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in Cancer.
- The interaction of genetic polymorphisms with lifestyle factors: implications for the dietary prevention of prostate Cancer.
- An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate Cancer cells.
- The AKT inhibitor perifosine in biochemically recurrent prostate Cancer: a phase II California/Pittsburgh Cancer consortium trial.
- Cost-benefit and outcome analysis: effect of Prostate biopsy undergrading.
- Biologic agents as adjunctive therapy for prostate Cancer: a rationale for use with androgen deprivation.
- Efficacy of transhepatic radiofrequency ablation of Renal cell carcinoma.
- Medical and surgical palliative care of patients with urological malignancies.
- Is the use of anything but MVAC justified in the evidence-based medicine era?
- Old friends, new ways: revisiting extended lymphadenectomy and neoadjuvant chemotherapy to improve outcomes.
- The economic burden of metastatic and prostate specific antigen progression in patients with prostate Cancer: findings from a retrospective analysis of health plan data.
- Testicular Cancer metastatic exclusively to the brain and spleen.
- Long-term safety and efficacy of tamsulosin for the treatment of lower Urinary tract symptoms associated with benign prostatic hyperplasia.
- Is Bladder biopsy necessary at three or six months post BCG therapy?
- Does retroperitoneal lymphadenectomy for testicular germ cell tumor require a different approach in the presence of horseshoe Kidney?
- Application of a yeast assay to detect functional p53 mutations in archival prostate Cancer tissue.
- Follow-up surveillance strategies for genitoUrinary malignancies.
- Targeting Btk/Etk of prostate Cancer cells by a novel dual inhibitor.
- CTA095, a Novel Etk and Src Dual Inhibitor, Induces Apoptosis in Prostate Cancer Cells and Overcomes Resistance to Src Inhibitors.
- What''s hot in the Prostate?
- Initial report of Bladder carcinoma following combined Bladder-drained pancreas and kidney transplantation.
- Minimally invasive therapies for benign prostatic hyperplasia.
- Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.
- Evidence-based medicine for the urologist.
- An evidence-based approach to understanding the pharmacological class effect in the management of prostatic Diseases.
- Society of Urologic Oncology position statement: redefining the management of hormone-refractory Prostate carcinoma.
- Management approaches to small Renal tumours.
- Minimising postoperative incontinence following radical Prostatectomy: considerations and evidence.
- Prostate Cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications.
- Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term th...
- Nonreceptor tyrosine kinases in prostate Cancer.
- Renal cell carcinoma: current status and emerging therapies.
- Non-surgical management of multicystic dysplastic Kidney.
- Current management of small Renal masses.
- Managing prostate Cancer: the role of hormone therapy.
- Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH).
- Current applications for Prostate-specific antigen doubling time.
- A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate Cancer: a California Cancer Consortium study.
- Identification of molecular targets in urologic oncology.
- The role of surveillance in the treatment of patients with muscle-invasive Bladder cancer after chemotherapy.
- MicroRNA in prostate, Bladder, and kidney cancer: a systematic review.
Schools
Dartmouth Medical School
Uc San Francisco
MD Anderson Cancer Center
University Of Vermont
Procedures Preformed
- AdRenalectomy
- Cystectomy
- Cystotomy
- Cystourethroplasty with Repair of Bladder Neck with Robotic Assistance
- View All
Conditions Treated
- Bladder Cancer
- Blood in Urine (Hematuria)
- Chronic Kidney Diseases
- Diverticulum of Bladder
- View All
Doctors Specialties
- Urology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Guided Access HMO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Select PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Delta Health System
- First Health (Coventry Health Care) PPO
- GEHA
- Blue & Gold HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- Humana
- Medicare MCR
- Molina
- MultiPlan PPO
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
- Western Health Advantage
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACS)
- Super Doctor
Education
-
University of Texas MD Anderson Cancer Center -
UCSF -
UCSF Medical Center -
Madigan Healthcare System -
Geisel School of Medicine at Dartmouth
Hospital
-
University of California, Davis Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Marc A. Dall'Era, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan A. Eandi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Theresa M. Koppie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alice K. Tsao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paolo Andreassi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander B. Cantrell, MD |
|
|
Dr. Thomas A. Pashalides, MD |